BCL2 and neoplasm: Studies have shown that GzmB can induce the accumulation of WT p53 in the mitochondria of target tumor cells and interact with the anti-apoptotic protein B-cell lymphoma-2 (BCL-2), thereby antagonizing the inhibitory effect of BCL-2 on the pro-apoptotic factors Bcl-2 Associated X-protein (BAX) and truncated Bid (tBid), contributing to a large release of BAX and tBid, thereby facilitating the release of cytochrome C from mitochondria and triggering the apoptosis of tumor cells [42].